<DOC>
	<DOCNO>NCT01870596</DOCNO>
	<brief_summary>This randomized phase II trial study well cytarabine without SCH 900776 work treat adult patient relapse acute myeloid leukemia . Drugs use chemotherapy , cytarabine , work different way stop growth cancer cell , either kill cell stop dividing . SCH 900776 may stop growth cancer cell block enzymes need cell growth . It yet know whether cytarabine effective without SCH 900776 treat acute myeloid leukemia .</brief_summary>
	<brief_title>Cytarabine With Without SCH 900776 Treating Adult Patients With Relapsed Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare rate complete remission ( CR ) plus CR incomplete recovery ( CRi ) achieve cytosine arabinoside ( ara-C ) ( cytarabine ) plus checkpoint kinase 1 ( CHK1 ) inhibitor MK-8776 ( Chk1 inhibitor SCH 900776 ) vs. ara-C alone adult ( age 18-75 ) relapse acute myelogenous leukemia ( AML ) . SECONDARY OBJECTIVES : I . To evaluate compare toxicity ara-C + MK-8776 vs. ara-C alone . II . To determine disease free overall survival achieve response treatment . III . To determine impact MK-8776 AML blast cell deoxyribonucleic acid ( DNA ) repair protein expression profile correlate expression profile CR/CRi response ara-C + MK-8776 vs. ara-C alone . IV . To evaluate compare amount DNA damage induce AML blast ara-C + MK-8776 vs. ara-C. OUTLINE : Patients randomize 1 2 treatment arm . ARM A : Patients receive cytarabine intravenously ( IV ) continuously 72 hour day 1-3 10-12 Chk1 inhibitor SCH 900776 IV 30 minute day 2 , 3 , 11 , 12 . ARM B : Patients receive cytarabine Arm A . In arm , course may repeat every 28 day . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Adults establish , pathologically confirm diagnosis relapse AML AML relapse least primary induction failure Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Patients must able give informed consent Female patient childbearing age must negative pregnancy test Serum creatinine = &lt; 2.0 mg/dl Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 5 x upper limit normal ( ULN ) , unless due Gilbert 's , hemolysis leukemic infiltration Alkaline phosphatase = &lt; 5 x ULN , unless due Gilbert 's , hemolysis leukemic infiltration Bilirubin = &lt; 2.0 mg/dl , unless due Gilbert 's , hemolysis leukemic infiltration Left ventricular ejection fraction &gt; = 45 % multi gated acquisition scan ( MUGA ) echocardiogram Baseline Fridericia correct QT ( QTcF ) &lt; 480 msec Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry 30 day study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Patients undergone stem cell transplantation ( SCT ) , autologous allogeneic , eligible provide &gt; = 4 week stem cell infusion , active graftvshost disease ( GVHD ) , meet eligibility criterion Patients fail primary induction therapy relapse achieve complete remission ( CR ) eligible undergone 2 prior cytotoxic regimen ( regimen describe distinctive plan collection agent [ ] and/or modality utilize together cycle course therapy ; i.e. , induction+consolidation without stem cell transplant [ SCT ] ) , &gt; = 2 week cytotoxic chemotherapy , &gt; = 2 week radiation therapy ; patient must biologic therapy include hematopoietic growth factor &gt; = 2 week ; use hydroxyurea ( HU ) , steroid , imatinib tyrosine kinase inhibitor ( TKIs ) , interferon , noncytotoxics blast count control , patient must &gt; = 24 hour ( hr ) start MK8776 Fluvoxamine ciprofloxacin must stop 7 day prior day 1 therapy , exclude administration study therapy ; subject use drug cytochrome P4501A2 ( CYP1A2 ) Pglycoprotein ( PgP ) inhibitor , substitution consider administration drug avoid day administration MK8776 ; addition , smoke avoid cytochrome P450 3A4 ( CYP3A4 ) substrates narrow therapeutic index avoid : alfentanil , astemizole , cisapride , cyclosporine , diergotamine , ergotamine , fentanyl , pimozide , quinidine , sirolimus , tacrolimus , terfenadine Any previous treatment MK8776 Considered refractory treatment failure recent treatment regimen , unless primary refractory Concomitant chemotherapy , radiation therapy , immunotherapy Hyperleukocytosis &gt; = 50,000 blasts/uL ( use HU , steroid , tyrosine kinase/src inhibitor ( include fmsrelated tyrosine kinase 3 [ FLT3 ] inhibitor ) , arsenic , interferon leukapheresis blast count control , patient must agent 24 hour prior begin araC +/ MK8776 ) Acute progranulocytic leukemia ( APL , M3 ) Active disseminate intravascular coagulation ( DIC ) Active central nervous system ( CNS ) leukemia Active , uncontrolled infection ; patient infection active treatment control antibiotic eligible Presence lifethreatening illness Patients mental deficit and/or psychiatric history preclude give informed consent follow protocol Pregnant woman exclude study ; breastfeed discontinue mother treated MK8776 History Fridericia correct QT ( QTcF ) prolongation great grade 1 480 msec Subjects follow cardiac risk factor must exclude : transmural myocardial infarction ( MI ) within prior 6 month , severe/unstable angina pectoris , coronary/peripheral artery bypass graft , cerebrovascular accident transient ischemic attack ( TIA ) seizure disorder within 6 month prior study drug administration Subjects history risk factor torsades de pointes : clinical history heart failure ( New York Heart Association [ NYHA ] class III IV ) , hypo hyperkalemia hypomagnesemia ( supplementation bring level within normal limit prior administration MK8776 acceptable ) family history Long QT Syndrome Human immunodeficiency virus ( HIV ) positive patient receive antiretroviral therapy prior history acquire immunodeficiency syndrome ( AIDS ) indicator condition , history lymphoma 3 year remote</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>